Blogs | Multibagger Shares

May 11, 2026

Hero Header with Title the Halo Effect and Subtitle Below is a Two by two Colored Grid Labeled Lucky gray Disciplined Investor green Confused light Gray Bias trapped orange

The Halo Effect: Thorndike’s 1920 Discovery and Phil Rosenzweig’s 2007 Warning

Edward Thorndike documented the halo effect in 1920; Phil Rosenzweig's 2007 book showed it runs backward in business commentary. We unpack the five Indian retail-investor halo channels, share a five-step de-haloing checklist, and use Titan Biotech FY25's nine decorrelated disclosed markers as an illustrative anti-halo process case study.

May 11, 2026

Bar Chart of 10 year Revenue Cagr Fy20fy25 Fy25 is Shown in Green at 11 with End Values 28 26 22 18 14 11

10-Year Revenue CAGR: The Foundational Top-Line Compounding Test Every Indian Long-Term Investor Must Master

How to read a 10-year Revenue CAGR through four disciplined lenses — illustrated with Titan Biotech FY25 audited numbers (~15% Revenue CAGR, ~29% PAT CAGR, ~103% CFO/OP, Rs.3 Cr borrowings). Educational only.

May 11, 2026

Large Page Header with the Title the Envyjealousy Tendency and Subtitle About Charlie Munger Set on a Dark Blue Background Below is a 2x2 Color Grid Labeled Lucky Disciplined Investor Confused and Bias trapped

The Envy/Jealousy Tendency: Charlie Munger’s 1995 Harvard Speech on Why It’s Not Greed That Drives the World

Charlie Munger's 1995 cognitive-bias #14 — the envy tendency — is the single cleanest explanation for India's ₹1.81 lakh crore F&O losses. Titan Biotech FY25's audited numbers read as a corporate version of the same discipline.

May 10, 2026

Title the Planning Fallacy with a Four panel Color Chart Labeled Lucky Disciplined Investor Confused and Bias trapped gray Green Light Gray Orange

The Planning Fallacy: Kahneman & Tversky’s 1979 Forecast Bias and Buehler-Griffin-Ross 1994 Discipline of Time-Cost-Risk Estimation

The Planning Fallacy systematically tricks investors into underestimating time, cost, and risk while overestimating benefits. Indian retail data shows the bias is alive and expensive — median expected returns of 18-22% versus actual Nifty 50 TR of 13.4%. The remedy is Reference-Class Forecasting. Titan Biotech FY25 illustrative numbers — Rs.3 cr borrowings (down 81%), 103% CFO/Operating Profit, paced capex over a decade.